Skip to content
Review Open access

ARTIFICIAL INTELLIGENCE-ENHANCED LIQUID BIOPSY IN CANCER MONITORING: FROM TREATMENT RESPONSE TO EARLY DETECTION OF DISEASE RECURRENCE

Sep 2026 · International Journal of Innovative Technologies in Social Science · 0 citations · 19 references

TL;DR

Current evidence indicates that AI can extract complementary biological information from complex circulating biomarker datasets, but prospective validation is still required before widespread implementation, and this review addresses major translational barriers.

Abstract

Liquid biopsy has emerged as an important minimally invasive technology in contemporary oncology, enabling repeated assessment of tumor-derived molecular information through blood and other biological fluids. Circulating tumor DNA (ctDNA), circulating tumor cells, cell-free DNA methylation patterns, extracellular vesicles, circulating RNA and fragmentomic signatures may provide dynamic information about tumor burden, treatment response, molecular residual disease and cancer recurrence. However, liquid biopsy generates complex, multidimensional datasets in which tumor-derived signals may be extremely small relative to biological and technical background. Artificial intelligence (AI), including machine learning and deep learning, offers a potential computational framework for integrating these heterogeneous signals and generating clinically meaningful predictions. This review examines the emerging convergence of AI and liquid biopsy, with particular emphasis on longitudinal cancer monitoring rather than cancer detection alone. The available PubMed-indexed literature was reviewed to evaluate the potential role of AI-enhanced liquid biopsy in treatment-response assessment, minimal residual disease detection, prediction of treatment resistance and early identification of disease recurrence. Evidence from colorectal, lung, breast, hepatocellular and other solid tumors is discussed. The review also addresses major translational barriers, including low tumor shedding, clonal hematopoiesis, analytical heterogeneity, external validation, algorithmic bias, interpretability, data privacy, cost and uncertainty regarding clinical actionability. Current evidence indicates that AI can extract complementary biological information from complex circulating biomarker datasets, but prospective validation is still required before widespread implementation. AI-enhanced liquid biopsy may ultimately support a transition from episodic, imaging-centered surveillance toward personalized, dynamic and molecularly informed cancer monitoring.

Read PDF

Similar papers

Review Open access Oct 2026

Can Liquid Biopsy Predict the Future of a Tumour? A Critical Review of AI-Enabled Longitudinal Modelling for Cancer Evolution and Treatment Resistance

This review critically examines whether longitudinal liquid-biopsy measurement, combined with artificial intelligence (AI), can move oncology from tumour monitoring toward genuine prediction of cancer evolution and treatment resistance.

Richard Afriyie Osei, Danmegoro Suleman Taiye, Godwin Kenechukwu Nwajiugo et al. · 0 citations
Review Open access Oct 2026

Liquid biopsy across cancers: Integrating circulating biomarkers, tumor biology, artificial intelligence, and clinical translation

The biological processes that influence ctDNA release, fragmentation, and clearance, including tumor cell turnover and cell death pathways, are discussed, as these directly affect its abundance in blood.

Jaswinder Singh, Manjeet Kumar, Kajal Kamra · 0 citations
Review Open access Sep 2026

Liquid biopsy in glioblastoma: emerging technologies and translational opportunities.

A multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics are introduced to enhance minimal residual disease detection and guide precision neuro-oncology.

Olawumi Giwa, Yonit Leykind, I. Altman et al. · 0 citations
Review Open access Sep 2026

Revolutionizing Lung Cancer Management: AI-Powered Liquid Biopsy–Immunotherapy Synergy For Early Internist-Led Interventions In High-Risk Populations

Lung cancer continues to be a predominant global cause of death. Clinical outcomes are significantly influenced by the timely identification of high-risk populations, accurate diagnosis, and appropriate therapy selection. Progress in artificial intelligence (AI), liquid biopsy, and immunotherapy has opened new avenues...

G. Pranowo, Gilang Prayoga Putra Permana, D. Selvyana · 0 citations
Review Oct 2026

Role of Liquid Biopsy in Cancer Diagnosis: A Comparative Evaluation with Conventional Techniques

Tissue biopsy and histopathological evaluation-considered the gold standard-are traditionally used for cancer diagnosis; however, these procedures are invasive and limited in their ability to accurately capture tumor heterogeneity. Liquid biopsy has emerged as a minimally invasive alternative that enables molecular...

Ankur Vashishtha, Azeem Rizvi, Asif Ali et al. · 0 citations
Review Open access Sep 2026

Liquid biopsy in bladder cancer: towards precision oncology

Bladder cancer (BC), as the most common form of urothelial carcinoma, represents a substantial global health burden owing to its high rates of late diagnosis and disease recurrence. Current standard diagnostics, such as cystoscopy and tissue biopsy, are invasive, costly, and limited in capturing tumor heterogeneity or...

Can Chen, Yu-Ze Yang, Zhou-Hui Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.